Mariyam Zuberi

Title
InstitutionMedical University of South Carolina
DepartmentPharmacology Allocation & Reserves
AddressP.O. Box MSC 509
HO702
Hollings Cancer Center - 86 Jonathan Lucas St.
Phone843-792-2277
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wallon L, Khan I, Teng KW, Koide A, Zuberi M, Li J, Ketavarapu G, Traaseth NJ, O'Bryan JP, Koide S. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket. Proc Natl Acad Sci U S A. 2022 10 25; 119(43):e2204481119. PMID: 36252024; PMCID: PMC9618066.
      Citations: 1     Fields:    Translation:Humans
    2. Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP, Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322. PMID: 35139380; PMCID: PMC8936000.
      Citations:    
    3. Khan I, MarElia-Bennet C, Lefler J, Zuberi M, Denbaum E, Koide A, Connor DM, Broome AM, Pécot T, Timmers C, Ostrowski MC, Koide S, O'Bryan JP, Khan I, Marelia-Bennet C, Lefler J, Zuberi M, Denbaum E, Koide A, Connor DM, Broome AM, P?cot T, Timmers C, Ostrowski MC, Koide S, O'Bryan JP. Targeting the KRAS a4-a5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases. 2022 Jan; 13(1):114-127. PMID: 33949915; PMCID: PMC9707541.
      Citations:    
    4. Zuberi M, Khan I, O'Bryan JP, Zuberi M, Khan I, O'Bryan JP. Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020 10 30; 48(5):1831-1841. PMID: 32869838; PMCID: PMC7875515.
      Citations:    
    5. Zuberi M, Dholariya S, Khan I, Mir R, Guru S, Bhat M, Sumi M, Saxena A, Zuberi M, Dholariya S, Khan I, Mir R, Guru S, Bhat M, Sumi M, Saxena A. Epigenetic Silencing of DAPK1and p16INK4a Genes by CpG Island Hypermethylation in Epithelial Ovarian Cancer Patients. Indian J Clin Biochem. 2021 Apr; 36(2):200-207. PMID: 33867711; PMCID: PMC7994475.
      Citations:    
    6. Zuberi M, Mir R, Khan I, Javid J, Guru SA, Bhat M, Sumi MP, Ahmad I, Masroor M, Yadav P, Vishnubhatla S, Saxena A, Zuberi M, Mir R, Khan I, Javid J, Guru SA, Bhat M, Sumi MP, Ahmad I, Masroor M, Yadav P, Vishnubhatla S, Saxena A. The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients. Microrna. 2020; 9(1):49-57. PMID: 30799804.
      Citations:    
    7. Zuberi M, Khan I, Mir R, Gandhi G, Ray PC, Saxena A, Zuberi M, Khan I, Mir R, Gandhi G, Ray PC, Saxena A. Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer. PLoS One. 2016; 11(4):e0153902. PMID: 27092777; PMCID: PMC4836713.
      Citations:    
    8. Zuberi M, Khan I, Gandhi G, Ray PC, Saxena A, Zuberi M, Khan I, Gandhi G, Ray PC, Saxena A. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer. Tumour Biol. 2016 Aug; 37(8):11259-66. PMID: 26951510.
      Citations:    
    Zuberi's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (52)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _